Notice of Clarification Regarding Letters of Collaboration in RFA-DA-15-007 "Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2)"

Notice Number: NOT-DA-14-029

Key Dates
Release Date: August 22, 2014

Related Announcements
RFA-DA-15-007

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

This Notice is to clarify that letters of collaboration are allowed in RFA-DA-15-007 "Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2)".

Part 2. Section IV.2. Content and Form of Application Package

SF424(R&R) Cover

Current language:
Cover Letter: Provide names and affilications of significant collaborators for the Avenir Award project. Letters of collaboration and biosketches of collaborators are not allowed. Provision of names here is only to help exclude conflicts during reviewer assignment. Information regarding any collaborators may be included in the Essay.

Revised Language:
Cover Letter: Provide names and affilications of significant collaborators for the Avenir Award project. Letters of collaboration are allowed, and should be uploaded via the Letters of Support attachment on the PHS 398 Research Plan form. Biosketches of collaborators are not allowed. Provision of names here is only to help exclude conflicts during reviewer assignment. Information regarding any collaborators may be included in the Essay.

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Jacques Normand, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1470
Email: jnormand@nida.nih.gov